# US 2019/0375843 A1 · Compositions and methods for modulating immune responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375843 A1
- Document ID: US20190375843A1
- Status: Published application
- Kind: A1
- Application number: 16/540,819
- Filed: 2019-08-14
- Published: 2019-12-12
- Earliest claimed: 2005-05-12
- Assignees: ZymoGenetics, Inc.
- Applicants: Zymogenetics, Inc.
- Inventors: Zeren GAO; Steven D. LEVIN; Janine M. BILSBOROUGH; James W. WEST; Cameron S. BRANDT; Eric M. Chadwick
- Web page: https://patentgrep.com/patent/US20190375843A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C12Q 1/66: involving luciferase
- G01N 33/505: {involving T-cells}
- G01N 33/56972: {White blood cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2333/70532: B7 molecules, e.g. CD80, CD86
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1′s ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

## Claims

### Claim 1

An agonist antibody or antibody fragment that specifically binds to a zB7R1 polypeptide comprising the amino acid sequence of residues 16-140 of SEQ ID NO: 2, wherein said antibody stimulates zB7R1-mediated signaling.

### Claim 2 (depends on 1)

The agonist antibody or antibody fragment of claim 1 wherein the antibody or antibody fragment is:
a) a human monoclonal antibody or antibody fragment thereof; or
b) a humanized monoclonal antibody derived from a murine a murine monoclonal antibody, or antibody fragment thereof.

### Claim 3 (depends on 1)

The agonist antibody or antibody fragment of claim 1 wherein the antibody or antibody fragment is an antibody fragment selected from the group consisting of F(ab′)2, Fab′, Fab, Fv, scFv, and minimal recognition unit.

### Claim 4 (depends on 1)

A method for treating an autoimmune disease comprising administering an agonist antibody or antibody fragment of claim 1 to a subject suffering from the autoimmune disease.

### Claim 5 (depends on 4)

The method of claim 4, wherein the autoimmune disease is rheumatoid arthritis.

### Claim 6 (depends on 4)

The method of claim 4, wherein the autoimmune disease is Crohn's disease or ulcerative colitis.

### Claim 7 (depends on 1)

A pharmaceutical formulation comprising:
a) the agonist antibody or antibody fragment according to claim 1; and
b) a pharmaceutically acceptable vehicle.
